well, the stix project isn't just for tex, it will also include a postscript type 1 and truetype font, be unicode compatable, and will have 7,000+ symbols.
TeX contains most math symbols, but is missing a lot of scientific symbols, and some people want to write their scientific paper in MS Word.
It is interesting, that Europe, home of 2 world wars, (and plenty of agression before that), multiple languages and multiple cultures is coming together to share currency, and now source code.
Of course, Europe is (currently) much more socialist than the US, and doesn't believe in software patents, fertile breeding ground for Open Source.
from the article: PayPal is a tad controversial - it's got jaw-dropping Ts&Cs and it's not very friendly to people outside the US. Also, there are occasional foul-ups, and several states want much closer scrutiny - if PayPal.looks like a bank and it acts like a bank, then it should regulated like a bank.
In fact, the article doesn't mention any ebay controversy. Expect this comment to be modded down and the story silently edited...
ok, not PacBell, but MCI (you know, MCI/Worldcom, the company that had to restate earnings for last year from +2 billion to -2 billion, the company that was fined in 1997 for overbilling), and not DSL, but regular long-distance phone service...
3-4 months ago, I switched from Verizon/MCI to a local company to provide both local & long distance service. Last week I recived a bill from MCI for $3.59 -- $3.00 "minimum usage fee" (when I was a customer, it was on a plan without a minimum usage fee) and $0.59 taxes. No wonder they can't tell if they're profitable or not. I forwarded a copy of the bill to the fcc and the state Attorney General. Maybe if I have a few hours to kill, I'll try to tell them I'm not a customer of theirs...
The industry average for overbilling is 10%. Most telcos use "accrual" accounting. Money is reported as recieved when a bill is sent out, not when payment is recieved. By overbilling, the bottom line looks 10% larger than it really is.
It's almost expected for posters to not read the article, but do the article submitter or editors even read it?
"The first plans for the new alloy are to be used in golf clubs, baseball bats, skis, and cell phone covers."
From the article: "Liquidmetal Technologies' first product was golf club heads..."
From their website: "Taking advantage of a revolutionary class of a next generation super alloy that was originally launched in golf clubs in 1998,..."
Apple isn't in the business of selling an OS, or even hardware. They're in the business of selling a user experience, a digital lifestyle, and they can only do that if they control the OS and the hardware. Rhapsody for x86 or "windows compatable" iPod may increase sales, but it also breaks apart the apple experience into pieces.
It might sound like marketting bullshit, but think about it... Coca Cola doesn't sell a can of carbonated sugar water, they sell an image. If you just want a soda, you could buy RC or Shasta or Kmart Cola. In Europe, you can even buy Coca Cola designer clothes.
good riddance to the stated requirement. IEEE has around 400,000 members in 150+ countries. Since they are one of the largest publishers of electrical engineering/computer science literature, they were effectively extending the DMCA's censorship beyond our borders to places like Autralia and Europe, where software can't even be patented.
That with Oilmen in the whitehouse that this project won't get underway anytime soon.
Diesel is made from oil.
On another note, if hydrogen fuel cell cars ever get off the ground, they could be plugged into the power grid when not in use and return electricity to it somehow?
Most canned hydrogen comes from water that is split (into O2 and H2) by passing an electrical charge through it, so it would be like eating your own vomit (or poop). At the rate wind turbines are popping up in the midwest, there will be plenty of electricity to spare anyhow.
I can't comment on current trends, but up into the mid 90s at least, Macs were quite popular in Japan (that's to say they had a larger percentage of the market than in the US). They had kanji support years ago.
I'd guess they've lost market share as Windows has improved and offered improved i18n support, as well as cooler hardware from Sony and Toshiba.
The Gov't could be a good market for apple, particularly now that they use OS X Gov't workers are getting tired of code red, nimda, etc, which hilite how insecure Windows is when not properly configured. Even though it would require new hardware, OS X has an advantage over linux due to native MS Office support, as well as more commercial applications.
This is their more optimistic response: (and actually, their site is currently down... http://pharmacia.com/News/PressReleases.asp)
Pharmacia Comments on Lancet Research Letter
PEAPACK, NJ (July 19, 2001) Pharmacia Corporation (NYSE: PHA)
commented today on a letter* being published in the July 21 issue of The Lancet
that reports the development of linezolid-resistant Staphylococcus aureus bacteria
in one patient.
Pharmacia in vitro studies and laboratory studies conducted by other researchers
have shown that linezolid-resistant S. aureus would develop infrequently. As a
result of this research, it is presumed that resistance would likely only occur in the most
extreme clinical conditions. These data have already been reported to the global medical
community. No other cases of linezolid-resistant S. aureus have been reported,
despite the fact that more than 80,000 patients have been treated worldwide with linezolid,
marketed by Pharmacia as ZYVOX(tm) (linezolid injection, tablets and for oral suspension)
in the US and 15 other countries.
One of the authors of the research letter, Robert Moellering, M.D., Chairman of the
Department of Medicine, Beth Israel Deaconess Medical Center, and Professor of
Medicine, Harvard Medical School, provided additional perspective to the case reported in
the research letter. "Despite the discovery of this single report of resistant S.
aureus, linezolid remains an important part of the physician's armamentarium for the
treatment of infections, including those due to resistant bacteria and one that may allow
patients to leave the hospital earlier."
"At each stage of the development and market introduction of ZYVOX, we have proactively
shared our research and knowledge with physicians and regulatory officials around the
globe," said Cameron Durrant, M.D., Vice President, Infectious Diseases, Global
Prescription Business, Pharmacia Corporation. "We are interested in the experience of all
patients treated with ZYVOX, including this specific patient, and are confident that the
unmatched efficacy and convenient formulations of ZYVOX will continue to provide great
potential benefit to patients."
Pharmacia's preclinical and clinical experience to date has defined the risk factors for
development of resistance. These are:
Indwelling prosthetic device
Long-term therapy
Inadequate dose
Undrained abscess
The patient history described in the letter to The Lancet is generally consistent with
these findings. Pharmacia continues to actively monitor for potential emerging resistance.
ZYVOX comes from the first completely new class of antibiotics to reach hospitals in 35
years. ZYVOX attacks bacteria in a way unlike any existing therapies. ZYVOX attacks
bacteria by stopping protein production at a very early point in the process that is different
from any other antibiotic. Studies have shown that ZYVOX is effective against a broad
range of Gram-positive bacteria including those that are resistant to other antibiotics.
ZYVOX is approved for adults in the treatment of nosocomial (i.e. hospital-acquired)
pneumonia, community-acquired pneumonia, complicated and uncomplicated skin and
skin structure infections caused by susceptible strains of designated organisms. ZYVOX
is also approved for use in complicated skin infections and nosocomial pneumonia caused
by certain sensitive and resistant pathogens, including methicillin-resistant
Staphylococcus aureus (MRSA).
ZYVOX is generally well tolerated. The adverse events reported for patients receiving
ZYVOX and comparators in clinical trials were similar. The most common adverse events
for patients treated with ZYVOX were diarrhea, nausea, headache and vomiting.
Myelosuppression has been reported in patients receiving ZYVOX. Therefore, complete
blood counts should be monitored weekly. Discontinuation of ZYVOX should be
considered in patients who develop or have worsening myelosuppression.
Pharmacia (NYSE: PHA) is a top-tier global pharmaceutical company with a leading
agricultural subsidiary. Pharmacia's innovative medicines and other products save lives
and enhance health and wellness. Pharmacia's 59,000 people work together with many
diverse stakeholders to bring these benefits to people around the world, and to create new
health solutions for the future.
*Tsiodras S, Gold H, Sakoulas G, et al. Linezolid resistance in a clinical isolate
of Staphylococcus aureus. The Lancet 358 (July 21, 2001):207-208.
Certain statements contained in these comments are "forward-looking statements"
provided under the "safe harbor" protection of the Private Securities Litigation Reform Act of
1995. Examples of forward-looking statements are anticipated financial results, financial
projections, business prospects, future product performance, future research and
development results, Expected regulatory actions and other matters that are not historical
facts. These forward-looking statements are based on the information available, and the
expectations and assumptions deemed reasonable by the Company, at the time when the
statements are made. However, because these forward-looking statements are subject to
many risks, uncertainties and changes over time, actual results may differ materially from
those expressed or implied by such forward-looking statements. Among the many factors
that may cause or contribute to actual results being materially different from those
expressed or implied by such forward-looking statements are acquisitions, divestitures,
mergers, licenses or strategic initiatives that change the Company' structure or business;
competitive effects from current and new products, including generic products, sold by
other companies; price constraints imposed by managed care groups, institutions and
government agencies; governmental actions to provide lower cost pharmaceutical products;
the Company' ability to continue to discover and license new compounds, develop product
candidates, obtain regulatory approvals and market new products; the Company' ability to
secure and defend its intellectual property rights; the Company' ability to attract and retain
management and other key employees; product developments, including adverse reactions
or regulatory actions; social, legal and political developments, especially those relating to
health care reform, pharmaceutical pricing and governmental and public acceptance of
biotechnology; unusual seasonal conditions in agricultural markets; new product, antitrust,
intellectual property or environmental liabilities; changes in foreign currency exchange
rates or general economic or business conditions; changes in applicable laws and
regulations; changes in accounting standards or practices; and such other factors that
may be described in Companies' filings with the U.S. Securities and Exchange
Commission.
And he published it in an attempt to discredit the lawsuit, by claiming that the people behind the suit were just trying to tear down ICANN.
There's a saying that's popular with defense laywers... "When you don't have the law, you argue the facts. When you don't have the facts, you argue the law. And when you don't have either, you persecute the prosecutor"
Slashdot Mirror
users would *voluntarily* put up with the ads to help fund open source development.
well, the stix project isn't just for tex, it will also include a postscript type 1 and truetype font, be unicode compatable, and will have 7,000+ symbols.
TeX contains most math symbols, but is missing a lot of scientific symbols, and some people want to write their scientific paper in MS Word.
Of course, Europe is (currently) much more socialist than the US, and doesn't believe in software patents, fertile breeding ground for Open Source.
I wonder if this online petition had any effect...
unfortunately, no credit is given for karma whoring or redirecting you to mr. goatse.
from the article:
PayPal is a tad controversial - it's got jaw-dropping Ts&Cs and it's not very friendly to people outside the US. Also, there are occasional foul-ups, and several states want much closer scrutiny - if PayPal.looks like a bank and it acts like a bank, then it should regulated like a bank.
In fact, the article doesn't mention any ebay controversy. Expect this comment to be modded down and the story silently edited...
Sure you do. How do you explain the hairy palms?
It's called "S & M".
3-4 months ago, I switched from Verizon/MCI to a local company to provide both local & long distance service. Last week I recived a bill from MCI for $3.59 -- $3.00 "minimum usage fee" (when I was a customer, it was on a plan without a minimum usage fee) and $0.59 taxes. No wonder they can't tell if they're profitable or not. I forwarded a copy of the bill to the fcc and the state Attorney General. Maybe if I have a few hours to kill, I'll try to tell them I'm not a customer of theirs...
The industry average for overbilling is 10%. Most telcos use "accrual" accounting. Money is reported as recieved when a bill is sent out, not when payment is recieved. By overbilling, the bottom line looks 10% larger than it really is.
"The first plans for the new alloy are to be used in golf clubs, baseball bats, skis, and cell phone covers."
From the article:
"Liquidmetal Technologies' first product was golf club heads..."
From their website: ..."
"Taking advantage of a revolutionary class of a next generation super alloy that was originally launched in golf clubs in 1998,
And scientific information here
Not sure if it's actually for sale yet, or just a prototype.
Apple isn't in the business of selling an OS, or even hardware. They're in the business of selling a user experience, a digital lifestyle, and they can only do that if they control the OS and the hardware. Rhapsody for x86 or "windows compatable" iPod may increase sales, but it also breaks apart the apple experience into pieces.
It might sound like marketting bullshit, but think about it... Coca Cola doesn't sell a can of carbonated sugar water, they sell an image. If you just want a soda, you could buy RC or Shasta or Kmart Cola. In Europe, you can even buy Coca Cola designer clothes.
good riddance to the stated requirement. IEEE has around 400,000 members in 150+ countries. Since they are one of the largest publishers of electrical engineering/computer science literature, they were effectively extending the DMCA's censorship beyond our borders to places like Autralia and Europe, where software can't even be patented.
Diesel is made from oil.
On another note, if hydrogen fuel cell cars ever get off the ground, they could be plugged into the power grid when not in use and return electricity to it somehow?
Most canned hydrogen comes from water that is split (into O2 and H2) by passing an electrical charge through it, so it would be like eating your own vomit (or poop). At the rate wind turbines are popping up in the midwest, there will be plenty of electricity to spare anyhow.
I'd guess they've lost market share as Windows has improved and offered improved i18n support, as well as cooler hardware from Sony and Toshiba.
Really? I keep looking for vanna white pics, but all I can find is that damn Weird Al song!
The Gov't could be a good market for apple,
particularly now that they use OS X
Gov't workers are getting tired of code red, nimda, etc, which hilite how insecure Windows is when not properly configured.
Even though it would require new hardware, OS X has an advantage over linux due to native MS Office support, as well as more commercial applications.
sshutup-theo.tar.gz
See here for the corresponding message.
here is the (french) website for one of these cars. They set the world-record of 3625km/liter
Pharmacia Comments on Lancet Research Letter
PEAPACK, NJ (July 19, 2001) Pharmacia Corporation (NYSE: PHA) commented today on a letter* being published in the July 21 issue of The Lancet that reports the development of linezolid-resistant Staphylococcus aureus bacteria in one patient.
Pharmacia in vitro studies and laboratory studies conducted by other researchers have shown that linezolid-resistant S. aureus would develop infrequently. As a result of this research, it is presumed that resistance would likely only occur in the most extreme clinical conditions. These data have already been reported to the global medical community. No other cases of linezolid-resistant S. aureus have been reported, despite the fact that more than 80,000 patients have been treated worldwide with linezolid, marketed by Pharmacia as ZYVOX(tm) (linezolid injection, tablets and for oral suspension) in the US and 15 other countries.
One of the authors of the research letter, Robert Moellering, M.D., Chairman of the Department of Medicine, Beth Israel Deaconess Medical Center, and Professor of Medicine, Harvard Medical School, provided additional perspective to the case reported in the research letter. "Despite the discovery of this single report of resistant S. aureus, linezolid remains an important part of the physician's armamentarium for the treatment of infections, including those due to resistant bacteria and one that may allow patients to leave the hospital earlier."
"At each stage of the development and market introduction of ZYVOX, we have proactively shared our research and knowledge with physicians and regulatory officials around the globe," said Cameron Durrant, M.D., Vice President, Infectious Diseases, Global Prescription Business, Pharmacia Corporation. "We are interested in the experience of all patients treated with ZYVOX, including this specific patient, and are confident that the unmatched efficacy and convenient formulations of ZYVOX will continue to provide great potential benefit to patients."
Pharmacia's preclinical and clinical experience to date has defined the risk factors for development of resistance. These are:
- Indwelling prosthetic device
- Long-term therapy
- Inadequate dose
- Undrained abscess
The patient history described in the letter to The Lancet is generally consistent with these findings. Pharmacia continues to actively monitor for potential emerging resistance.ZYVOX comes from the first completely new class of antibiotics to reach hospitals in 35 years. ZYVOX attacks bacteria in a way unlike any existing therapies. ZYVOX attacks bacteria by stopping protein production at a very early point in the process that is different from any other antibiotic. Studies have shown that ZYVOX is effective against a broad range of Gram-positive bacteria including those that are resistant to other antibiotics.
ZYVOX is approved for adults in the treatment of nosocomial (i.e. hospital-acquired) pneumonia, community-acquired pneumonia, complicated and uncomplicated skin and skin structure infections caused by susceptible strains of designated organisms. ZYVOX is also approved for use in complicated skin infections and nosocomial pneumonia caused by certain sensitive and resistant pathogens, including methicillin-resistant Staphylococcus aureus (MRSA).
ZYVOX is generally well tolerated. The adverse events reported for patients receiving ZYVOX and comparators in clinical trials were similar. The most common adverse events for patients treated with ZYVOX were diarrhea, nausea, headache and vomiting. Myelosuppression has been reported in patients receiving ZYVOX. Therefore, complete blood counts should be monitored weekly. Discontinuation of ZYVOX should be considered in patients who develop or have worsening myelosuppression.
Pharmacia (NYSE: PHA) is a top-tier global pharmaceutical company with a leading agricultural subsidiary. Pharmacia's innovative medicines and other products save lives and enhance health and wellness. Pharmacia's 59,000 people work together with many diverse stakeholders to bring these benefits to people around the world, and to create new health solutions for the future.
*Tsiodras S, Gold H, Sakoulas G, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. The Lancet 358 (July 21, 2001):207-208. Certain statements contained in these comments are "forward-looking statements" provided under the "safe harbor" protection of the Private Securities Litigation Reform Act of 1995. Examples of forward-looking statements are anticipated financial results, financial projections, business prospects, future product performance, future research and development results, Expected regulatory actions and other matters that are not historical facts. These forward-looking statements are based on the information available, and the expectations and assumptions deemed reasonable by the Company, at the time when the statements are made. However, because these forward-looking statements are subject to many risks, uncertainties and changes over time, actual results may differ materially from those expressed or implied by such forward-looking statements. Among the many factors that may cause or contribute to actual results being materially different from those expressed or implied by such forward-looking statements are acquisitions, divestitures, mergers, licenses or strategic initiatives that change the Company' structure or business; competitive effects from current and new products, including generic products, sold by other companies; price constraints imposed by managed care groups, institutions and government agencies; governmental actions to provide lower cost pharmaceutical products; the Company' ability to continue to discover and license new compounds, develop product candidates, obtain regulatory approvals and market new products; the Company' ability to secure and defend its intellectual property rights; the Company' ability to attract and retain management and other key employees; product developments, including adverse reactions or regulatory actions; social, legal and political developments, especially those relating to health care reform, pharmaceutical pricing and governmental and public acceptance of biotechnology; unusual seasonal conditions in agricultural markets; new product, antitrust, intellectual property or environmental liabilities; changes in foreign currency exchange rates or general economic or business conditions; changes in applicable laws and regulations; changes in accounting standards or practices; and such other factors that may be described in Companies' filings with the U.S. Securities and Exchange Commission.
been there, done that
There's a saying that's popular with defense laywers ... "When you don't have the law, you argue the facts. When you don't have the facts, you argue the law. And when you don't have either, you persecute the prosecutor"
Find a pool, pond, or river, preferably with lots of hot girls around, then jump right in!